BPC-157

How it works

BPC-157 is a 15-amino-acid peptide based on a protective protein found naturally in human gastric juice. Its standout property is supporting tissue repair: it promotes the growth of new blood vessels (via VEGF receptor 2 signalling), interacts with the nitric oxide system, and supports fibroblast activity involved in wound healing. Unlike most compounds in this guide, its focus isn’t calming inflammation but helping damaged tissue rebuild — a genuinely different angle on gut health. It is also unusually stable in stomach acid.

Traditional use

Not a traditional remedy — BPC-157 is a modern research peptide, first described by a Croatian research group in the early 1990s and derived from a protein in human gastric juice.

Highlights

• In animal studies, BPC-157 accelerated healing of intestinal anastomoses, with better collagen formation and tissue regrowth.
• Closed colocutaneous fistulas in animal models — relevant to fistulising Crohn’s, which remains hard to manage.
• Entered formal clinical trials for inflammatory bowel disease and was reported safe.
• Focuses on tissue repair rather than immune suppression — a complementary approach.
• Not approved for human use anywhere, so it is not available as a supplement. Interest is growing in formal research.

What the research shows

Every study below links to its original publication so you can read it yourself. Many natural compounds have only been studied in small trials. That isn’t a verdict on them; it reflects how little funding exists for compounds that can’t be patented.

Using it alongside conventional care

BPC-157 attracts a lot of interest from people exploring alternatives to biologics like Humira, Remicade, Stelara and Entyvio, but it works in a completely different way. Those medications calm the immune signals that drive inflammation. BPC-157 is studied for helping tissue that is already damaged to repair itself. If the research translates to people, that would make it a complement to immune-focused therapy rather than a replacement — especially interesting for post-surgical healing and fistulas. For now it remains an investigational compound, so the right path is through clinical research rather than self-sourcing.

Never stop or change a prescribed medication without your gastroenterologist. Many people use natural support alongside conventional care, and your care team can help you do that safely.

Amounts used in research

Animal studies commonly use 10 ng–10 µg per kilogram. No validated human dose exists for Crohn’s disease, and doses circulating in consumer communities are extrapolated from rodent work rather than derived from human pharmacokinetics.

Good to know

• No adequate long-term human safety data exist at any dose.
• Its central mechanism is pro-angiogenic, which is a theoretical concern in a population with elevated baseline colorectal cancer risk from long-standing inflammation.
• Not approved as a drug in any jurisdiction; products sold as BPC-157 are unregulated and frequently misidentified or contaminated on independent analysis.
• Prohibited at all times under the World Anti-Doping Agency code.
• Injectable use by consumers carries sterility and dosing risks entirely separate from the molecule itself.

Community experiences

Sources

1. 1

   Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat

   Vuksic T, Zoricic I, Brcic L, et al. · Surgery Today · 2007 · PMID 17713731

2. 2

   Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system

   Klicek R, Sever M, Radic B, et al. · Journal of Pharmacological Sciences · 2008 · PMID 18818478

3. 3

   Revised Robert’s cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157

   Sikiric P, Seiwerth S, Brcic L, et al. · Current Pharmaceutical Design · 2010 · PMID 20388078